Drug development

ASCO 2024 – Takeaways from Five Key Studies

If you didn’t get to attend the 2024…
Read Article

Embracing AI in Clinical Trials: An Oncology CRO’s Insight

In our previous article, we outlined how AI…
Read Article

Transforming Oncology Drug Development with Artificial Intelligence

The release of GPT 3.5 and the improvement…
Read Article

Preparing for Your Phase I Oncology Study

The phase 1 study is the gateway between…
Read Article

How Immune-related Response Criteria Is Changing Immunotherapy Treatments

Immune-related response criteria (irRC) is an essential tool…
Read Article

The PD-1 Era Is Officially Here

On July 4th Ono Pharmaceuticals announced that it…
Read Article

“Context of vulnerability” and its role in targeted drug development

Renowned cancer researcher Dr. Daniel Von Hoff and…
Read Article

The “Lost Opportunity” in Phase I Oncology Trials

Cancer drug developers traditionally use the phase I…
Read Article

Personalized Genomics: The First Report of a Cancer Genome

As reported by the New York Times last…
Read Article